Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Mitral Valve Regurgitation
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
-
University of Alabama Birmingham (UAB), Birmingham, Alabama, United States, 35233
Abrazo Heart Hospital, Phoenix, Arizona, United States, 85018
Scripps Memorial Hospital, La Jolla, California, United States, 92037
PIH Health Good Samaritan Hospital, Los Angeles, California, United States, 90017
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States, 90027
Keck Hospital of the University of Southern California, Los Angeles, California, United States, 90033
Cedars Sinai Medical Center, Los Angeles, California, United States, 90048
El Camino, Mountain View, California, United States, 94040
Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States, 94118-3100
Stanford Hospital and Clinics, Stanford, California, United States, 94305
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Medtronic Cardiovascular,
Michael Mack, MD, STUDY_CHAIR, Baylor Scott & White Hospital
David Adams, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai
Martin Leon, MD, PRINCIPAL_INVESTIGATOR, New York Presbyterian Hospital/Columbia University Medical Center
2036-09-30